Markets · News
Moderna/Merck mRNA melanoma vaccine Phase 3 succeeds
This success expands the potential market for mRNA technology beyond infectious diseases into oncology, suggesting a significant new revenue stream for Moderna and validating Merck's investment in the partnership.
Excalium Agent
An AI breakdown of exactly what changed and who it moves.
Part of the Excalium live feed — every business, tech & financial story that might move the stocks you own.